Literature DB >> 33484281

3D culture conditions support Kaposi's sarcoma herpesvirus (KSHV) maintenance and viral spread in endothelial cells.

Tatyana Dubich1, Anne Dittrich1, Kristine Bousset2, Robert Geffers3, Guntram Büsche4, Mario Köster1, Hansjörg Hauser5, Thomas F Schulz6,7,8, Dagmar Wirth9,10,11.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is a human tumorigenic virus and the etiological agent of an endothelial tumor (Kaposi's sarcoma) and two B cell proliferative diseases (primary effusion lymphoma and multicentric Castleman's disease). While in patients with late stage of Kaposi's sarcoma the majority of spindle cells are KSHV-infected, viral copies are rapidly lost in vitro, both upon culture of tumor-derived cells or from newly infected endothelial cells. We addressed this discrepancy by investigating a KSHV-infected endothelial cell line in various culture conditions and in tumors of xenografted mice. We show that, in contrast to two-dimensional endothelial cell cultures, KSHV genomes are maintained under 3D cell culture conditions and in vivo. Additionally, an increased rate of newly infected cells was detected in 3D cell culture. Furthermore, we show that the PI3K/Akt/mTOR and ATM/γH2AX pathways are modulated and support an improved KSHV persistence in 3D cell culture. These mechanisms may contribute to the persistence of KSHV in tumor tissue in vivo and provide a novel target for KS specific therapeutic interventions. KEY MESSAGES: In vivo maintenance of episomal KSHV can be mimicked in 3D spheroid cultures 3D maintenance of KSHV is associated with an increased de novo infection frequency PI3K/Akt/mTOR and ATM/ γH2AX pathways contribute to viral maintenance.

Entities:  

Keywords:  3D culture; Episomal viral genomes; KSHV infected endothelial cells; Viral maintenance; Xenograft model

Mesh:

Substances:

Year:  2021        PMID: 33484281      PMCID: PMC7900040          DOI: 10.1007/s00109-020-02020-8

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  66 in total

Review 1.  Directed egress of animal viruses promotes cell-to-cell spread.

Authors:  David C Johnson; Mary T Huber
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  clusterProfiler: an R package for comparing biological themes among gene clusters.

Authors:  Guangchuang Yu; Li-Gen Wang; Yanyan Han; Qing-Yu He
Journal:  OMICS       Date:  2012-03-28

3.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients.

Authors:  Giovanni Stallone; Antonio Schena; Barbara Infante; Salvatore Di Paolo; Antonella Loverre; Giulio Maggio; Elena Ranieri; Loreto Gesualdo; Francesco Paolo Schena; Giuseppe Grandaliano
Journal:  N Engl J Med       Date:  2005-03-31       Impact factor: 91.245

4.  Two-step activation of ATM by DNA and the Mre11-Rad50-Nbs1 complex.

Authors:  Aude Dupré; Louise Boyer-Chatenet; Jean Gautier
Journal:  Nat Struct Mol Biol       Date:  2006-04-23       Impact factor: 15.369

5.  Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen.

Authors:  M E Ballestas; P A Chatis; K M Kaye
Journal:  Science       Date:  1999-04-23       Impact factor: 47.728

6.  An endothelial cell line infected by Kaposi's sarcoma-associated herpes virus (KSHV) allows the investigation of Kaposi's sarcoma and the validation of novel viral inhibitors in vitro and in vivo.

Authors:  Tatyana Dubich; Anna Lieske; Susann Santag; Guillaume Beauclair; Jessica Rückert; Jennifer Herrmann; Jan Gorges; Guntram Büsche; Uli Kazmaier; Hansjörg Hauser; Marc Stadler; Thomas F Schulz; Dagmar Wirth
Journal:  J Mol Med (Berl)       Date:  2019-01-04       Impact factor: 4.599

7.  In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma.

Authors:  Agata D'Agostino Mutlu; Lucas E Cavallin; Loïc Vincent; Chiara Chiozzini; Pilar Eroles; Elda M Duran; Zahra Asgari; Andrea T Hooper; Krista M D La Perle; Chelsey Hilsher; Shou-Jiang Gao; Dirk P Dittmer; Shahin Rafii; Enrique A Mesri
Journal:  Cancer Cell       Date:  2007-03       Impact factor: 31.743

8.  Viral oncogene-induced DNA damage response is activated in Kaposi sarcoma tumorigenesis.

Authors:  Sonja Koopal; Johanna H Furuhjelm; Annika Järviluoma; Sari Jäämaa; Pawan Pyakurel; Christel Pussinen; Maria Wirzenius; Peter Biberfeld; Kari Alitalo; Marikki Laiho; Päivi M Ojala
Journal:  PLoS Pathog       Date:  2007-09-07       Impact factor: 6.823

9.  A role for MRE11, NBS1, and recombination junctions in replication and stable maintenance of EBV episomes.

Authors:  Jayaraju Dheekollu; Zhong Deng; Andreas Wiedmer; Matthew D Weitzman; Paul M Lieberman
Journal:  PLoS One       Date:  2007-12-05       Impact factor: 3.240

10.  Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation.

Authors:  Jungang Chen; Lu Dai; Alana Goldstein; Haiwei Zhang; Wei Tang; J Craig Forrest; Steven R Post; Xulin Chen; Zhiqiang Qin
Journal:  PLoS Pathog       Date:  2019-12-02       Impact factor: 6.823

View more
  3 in total

1.  Herpesvirus-induced spermidine synthesis and eIF5A hypusination for viral episomal maintenance.

Authors:  Un Yung Choi; Jae Jin Lee; Angela Park; Kyle L Jung; Shin-Ae Lee; Youn Jung Choi; Hye-Ra Lee; Chih-Jen Lai; Hyungjin Eoh; Jae U Jung
Journal:  Cell Rep       Date:  2022-08-16       Impact factor: 9.995

2.  SMER28 Attenuates PI3K/mTOR Signaling by Direct Inhibition of PI3K p110 Delta.

Authors:  Marco Kirchenwitz; Stephanie Stahnke; Silvia Prettin; Malgorzata Borowiak; Laura Menke; Christian Sieben; Carmen Birchmeier; Klemens Rottner; Theresia E B Stradal; Anika Steffen
Journal:  Cells       Date:  2022-05-16       Impact factor: 7.666

Review 3.  Recent Advances in Developing Treatments of Kaposi's Sarcoma Herpesvirus-Related Diseases.

Authors:  Eleonora Naimo; Jasmin Zischke; Thomas F Schulz
Journal:  Viruses       Date:  2021-09-09       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.